- Home » News and EventsPage 14
NEWS & EVENTS
Our newest offerings and capabilities. Recent investments in network capacity, new and expanded services and expertise. Upcoming conferences and events.
Catalent Signs Commercial Supply Agreement with Blueprint Medicines Following FDA Approval of GAVRETO™ (pralsetinib)
Nov 23, 2020
Catalent today announced that it had entered into a commercial supply agreement with Blueprint Medicines following FDA approval of GAVRETO™ (pralsetinib).
Catalent Appoints Dr. Behzad Mahdavi as Vice President of Open Innovation, Biologics, Cell and Gene Therapy
Nov 19, 2020
Catalent appoints Behzad Mahdavi, Ph.D., MBA, as Vice President of Open Innovation, Biologics, Cell and Gene Therapy. Dr. Mahdavi will join a team of experts to accelerate the adoption of new development and drug delivery technologies, and scalable manufacturing processes and techniques.
Catalent Completes Acquisition of Cell Therapy Manufacturing Facility from Bone Therapeutics
Nov 16, 2020
Catalent has completed the acquisition of Bone Therapeutics’ cell therapy manufacturing subsidiary, Skeletal Cell Therapy Support SA (SCTS), including all of its assets located in Gosselies, Belgium.
Taysha Gene Therapies Bolsters Manufacturing Capacity Through Partnership with Catalent
Nov 5, 2020
Taysha Gene Therapies and Catalent today announced a partnership to support the development and manufacturing of Taysha’s gene therapies at Catalent’s Maryland-based gene therapy facilities.
Catalent and BrainStorm Cell Therapeutics Announce Partnership for the Manufacture of Mesenchymal Stem Cell Platform Therapy NurOwn®
Oct 22, 2020
Catalent and BrainStorm Cell Therapeutics Inc announced an agreement for the manufacture of NurOwn®, BrainStorm’s autologous cellular therapy being investigated for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease or motor neuron disease.
Catalent to Discuss Data-Driven Development and Patient-Focused Dose Design Strategies at AAPS PharmSci 360
Oct 20, 2020
Catalent today announced that its experts will present at the upcoming American Association of Pharmaceutical Scientists (AAPS) PharmSci 360 event, which takes place virtually from Oct. 26 – Nov. 5, 2020.
Catalent Launches OptiGel® DR, a Delayed/Enteric Release Softgel for Pharmaceutical and Nutraceutical Applications
Oct 19, 2020
Catalent today announced the launch of OptiGel® DR technology for the formulation and manufacture of delayed/enteric release softgels. The technology allows softgel capsules to be formed by combining pectin, a naturally derived polysaccharide, with gelatin, eliminating the need for a separate capsule coating step.
Catalent to Discuss Innovative Approaches to Achieving T-Cell Commercial Readiness at Upcoming Industry Conference
Oct 12, 2020
Catalent today announced that Jesse Trekker, Ph.D., Business Director, Strategic Partnerships, Catalent Cell & Gene Therapy, will present at the Allogeneic Cell Therapies Summit, which will take place virtually on 26 – 28 October, 2020.
Innovation in Oncology, Cell & Gene Technology, and Post-COVID-19 Pharma Outlook to be Discussed by Catalent at CPhI
Oct 6, 2020
Catalent today announced that it will be participating in several roundtables alongside other leading industry experts at the CPhI Festival of Pharma, which is taking place virtually between Oct. 5 – 16, 2020.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.